Evidence map›Paper›PMID 40352626›Full record

ArticleCase reports in dermatology

A Rare Case of Primary Cutaneous CD4+ Small/Medium Size T-Cell Lymphoproliferative Disorder Responding to Rituximab.

Saman Al-Zahawi, Sara Masoomi, Alireza Ghanadan, Yasaman Sadeghi, Maryam Daneshpazhooh, Hamidreza Mahmoudi

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Case reports in dermatology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Saman Al-ZahawiDepartment of Dermatology, Razi Hospital, Tehran University of Medical Sciences (TUMS), Tehran, Iran.
Sara MasoomiDepartment of Dermatology, Razi Hospital, Tehran University of Medical Sciences (TUMS), Tehran, Iran.
Alireza GhanadanDepartment of Dermatopathology, Razi Hospital, Tehran University of Medical Sciences (TUMS), Tehran, Iran.
Yasaman SadeghiDepartment of Dermatology, Razi Hospital, Tehran University of Medical Sciences (TUMS), Tehran, Iran.
Maryam DaneshpazhoohDepartment of Dermatology, Razi Hospital, Tehran University of Medical Sciences (TUMS), Tehran, Iran.
Hamidreza MahmoudiDepartment of Dermatology, Razi Hospital, Tehran University of Medical Sciences (TUMS), Tehran, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Primary cutaneous CD4+ small/medium T-cell lymphoproliferative disorder is a rare lymphoproliferative disorder (PCS-TCLPD) characterized by a solitary erythematous plaque or nodule on the face, neck, or upper trunk with a favorable outcome. Very rarely, multiple plaques or masses may be seen in which precise evaluation should be performed to exclude other primary cutaneous lymphoma. Case Presentation: Here we report a rare case of recalcitrant primary cutaneous small-/medium-sized CD4+ lymphoproliferative disorder in a 55-year-old male patient who responded well to rituximab injection but had recurrence after 1 year from the injections. Conclusion: Aggressive treatment is avoided in solitary lesions of PCS-TCLPD, but multiple lesions with no response to the conventional modalities may need more sophisticated management, including anti-CD20 rituximab.

Indexed as

Cutaneous T-cell lymphomaPrimary cutaneous CD4+ small/medium T-cell lymphoproliferative disorderRituximab

Identifiers

PMID40352626
PMCPMC12064157

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.